Study S001015

Adjunctive Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: a Randomized, Double-Blind, Placebo-Controlled Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04466345
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 72
Start: 2021-10-06
Primary completion: 2024-12-27
Lead sponsor: University Health Network, Toronto
Conditions: Major Depressive Disorder
Interventions: BIOLOGICAL:Semaglutide; BIOLOGICAL:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Executive Function Composite Score [16 Weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003091	Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Badulescu S, Med (New York, N.Y.)	2026	Randomized trial	PMID 41218611 DOI	cites ClinicalTrials.gov:NCT04466345; registry reference DERIVED:41218611
R0008734	Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. Gill H, JAMA psychiatry	2026	Randomized trial	PMID 42054055 DOI	cites ClinicalTrials.gov:NCT04466345; registry reference DERIVED:42054055